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Abstract
Objective. To formulate timely evidence-based
guidelines for the management of opioid-induced
bowel dysfunction.
Setting. Constipation is a major untoward effect of
opioids. Increasing prescription of opioids has cor-
related to increased incidence of opioid-induced
constipation. However, the inhibitory effects of opi-
oids are not confined to the colon, but also affect
higher segments of the gastrointestinal tract, lead-
ing to the coining of the term “opioid-induced
bowel dysfunction.”
Methods. A literature search was conducted using
Medline, EMBASE, and EMBASE Classic, and the
Cochrane Central Register of Controlled Trials.
Predefined search terms and inclusion/exclusion
criteria were used to identify and categorize rele-
vant papers. A series of statements were formulated
and justified by a comment, then labeled with the
degree of agreement and their level of evidence as
judged by the Strength of Recommendation
Taxonomy (SORT) system.
Results. From a list of 10,832 potentially relevant
studies, 33 citations were identified for review.
Screening the reference lists of the pertinent papers
identified additional publications. Current defin-
itions, prevalence, and mechanism of opioid-
induced bowel dysfunction were reviewed, and a
treatment algorithm and statements regarding pa-
tient management were developed to provide
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guidance on clinical best practice in the manage-
ment of patients with opioid-induced constipation
and opioid-induced bowel dysfunction.
Conclusions. In recent years, more insight has
been gained in the pathophysiology of this “entity”;
new treatment approaches have been developed,
but guidelines on clinical best practice are still lack-
ing. Current knowledge is insufficient regarding
management of the opioid side effects on the upper
gastrointestinal tract, but recommendations can be
derived from what we know at present.
Key Words. Opioids; Constipation; Opioid
Antagonists; PAMORAs; Laxatives
Introduction
Pain, when not effectively treated and relieved, has det-
rimental effects on all aspects of a patient’s quality of
life (QoL) [1]. Opioids represent the cornerstone of pain
treatment, being the most commonly prescribed medi-
cation to treat severe pain in the Western world [2].
Opioids are increasingly used for the treatment also of
noncancer pain [3]. However, opioids are associated
with side effects, which include sedation, physical de-
pendence, respiratory depression, and gastrointestinal
(GI)-related side effects [4]. These side effects can dir-
ectly reduce patient QoL and increase medical service
use, but may also be dose limiting, thus affecting pain
control [5,6]. While tolerance develops to most side ef-
fects, GI side effects remain an ongoing problem for the
majority of patients [5].
GI-related side effects are mediated through the binding
of opioid agonists to l-receptors located in the enteric
nervous system, which causes increased nonpropulsive
contractions and inhibition of water and electrolyte ex-
cretion, leading to delayed GI transit and hard, infre-
quent stools [4,7,8]. A less common side effect of
opioids is narcotic bowel syndrome (NBS), characterized
by a paradoxical increase in abdominal pain associated
with continuous or increasing doses of opioids [9].
GI-related side effects, which include constipation, nau-
sea, vomiting, dry mouth, gastro-oesophageal reflux,
abdominal cramping, spasms, and bloating, are collect-
ively known as opioid-induced bowel dysfunction (OIBD)
[4,10]. Opioid-induced constipation (OIC) is the most
frequently reported and persistent side effect in patients
receiving opioids for analgesia [11]. This review aims to
evaluate the current understanding of OIBD and provide
timely evidence-based recommendations for the man-
agement of patients affected by this condition.
Methods
A search of the medical literature was conducted using
Medline (1946–September 2014), EMBASE and
EMBASE Classic (1947–September 2014), and The
Cochrane Central Register of Controlled Trials.
Potentially relevant studies were identified using the
terms listed in the Appendix. Using further search terms
(also listed in the Appendix), the identified studies were
categorized as relating to prevalence, epidemiology,
mechanisms, nonpharmacological treatment, pharmaco-
logical treatment, and treatment with opioid antagonists.
In total, the search yielded 10,832 unique citations
(Figure 1). For inclusion, all studies were required to be
performed in a population of adults who were receiving
opioids and who had a confirmed diagnosis of OIBD
based on clinical symptoms, physician’s opinion, or
diagnostic criteria specified by study investigators.
Studies identified within the treatment categories were
also required to be randomized controlled trials (RCTs),
comparing pharmacological or nonpharmacological
therapies with a control measure. There was no min-
imum duration of therapy, but quantitative assessment
of response to therapy was required. Results had to be
supplemented by negative investigations (e.g., colonos-
copy) where deemed necessary by the trial. Only publi-
cations in English were included in the analysis. Using
the above inclusion and exclusion criteria, the identified
citations were screened independently by two investiga-
tors for relevance by title and then abstract, which re-
sulted in 124 and 52 citations, respectively. Full
publications of the 52 citations were assessed, and, fol-
lowing discussion to resolve any disagreement, a final
list of 33 citations was generated [12–44]. Screening the
reference lists of the pertinent papers identified add-
itional publications.
Statements were then formulated and justified by a
comment. The statements were labeled with the degree
of agreement (usually unanimous) and their level of evi-
dence by the strength of recommendation taxonomy
(SORT) system (level 1¼ high; level 2¼moderate; level
3¼ low) [45]. This corresponds to the classification by
the GRADE system where the levels of evidence “low”
and “very low” are pooled [46]. The strength of recom-
mendation is given as “strong” or “weak” when applic-
able. Independent electronic voting was carried out after
a joint meeting where all authors had the possibility to
discuss the different sections and comment on each
statement. The table showing the results can be found
in the Appendix.
Definition, Symptoms, and Assessment of OIC and
OIBD
The Definition of OIC/OIBD Is Based on a Clinical
Evaluation Relating to a Change in Bowel Habits
During Opioid Therapy
Comment: Previously, the diagnosis was arbitrarily
based on changes in bowel function temporally associ-
ated with intake of opioids. A recent working group
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suggested that OIC was defined as follows: A change
when initiating opioid therapy from baseline bowel habits
(over 7 days) that is characterized by any of the follow-
ing: reduced bowel movement frequency, development
or worsening of straining to pass bowel movements, a
sense of incomplete rectal evacuation, or harder stool
consistency [47]. A somewhat comparable definition
was recently suggested based on a systematic literature
review [48]. These definitions represent the first attempts
to ensure a uniform diagnosis, and this definition is rec-
ommended for future studies to ensure a uniform
terminology.
The Symptoms of OIC Are Related to the Colon,
Whereas OIBD Manifests with Symptoms
Throughout the GI Tract
Comment: Opioid receptors are present throughout the
GI tract, and therefore symptoms should not be re-
stricted to the colon [49]. OIBD is a distressing condition
that manifests through a variety of different symptoms,
including vomiting, dry mouth, abdominal pain, gastro-
esophageal reflux, and constipation [4]. Descriptive
studies have demonstrated that patients undergoing
opioid treatment also had prevalent complaints related
to the upper gut [17,20,30]. However, most clinical
studies looking into adverse effects of opioids and opi-
oid antagonists have focused on OIC, and especially on
the number of complete bowel movements that can be
quantified. It should also be stressed that straining at
stools can cause upper GI symptoms such as reflux,
and it is therefore questionable as to whether OIC and
OIBD can be distinguished in clinical settings.
OIBD symptoms are potentially difficult to localize and
distinguish from each other due to the complex organ-
ization of the visceral sensory system; visceral afferents
show diffuse termination over many segments of the
spinal cord [50–52]. It is therefore plausible that colonic
distension due to OIC may also be felt in the upper
abdomen. Furthermore, mechanisms such as viscero-
visceral hyperalgesia may play a role for symptom
manifestations as afferents from somatic structures, and
different visceral organs often terminate on the same
neurons in the spinal cord [53–55]. As a consequence,
it has been shown that the acidification of the esopha-
gus may result in widespread changes in pain percep-
tion from remote organs, such as the rectum [56–58].
Although not investigated in detail, it seems plausible
that opioid treatment also results in widespread symp-
toms in most patients.
Importantly, while the effect on pain may decrease dur-
ing continuing opioid treatment, OIC tends to remain a
clinical problem and is not subject to tolerance [59].
Subjective Reports of OIC Are Based on Validated
Questionnaires, Whereas There Is No Consensus
About Assessment of OIBD
Comment: In many studies, symptom assessments
were based on self-made questionnaires.
Questionnaires developed and validated to assess “nor-
mal” constipation, such as the Bristol Stool Form Scale,
Patient Assessment of Constipation Scale, and the
Knowles-Eccersley-Scott symptom scoring system,
have also been used, although the sensitivity of these
Figure 1 Flow diagram showing review of literature to identify clinical research papers relating to OIBD.
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questionnaires when used by opioid users has not been
assessed [37,47,60]. Alongside the introduction of slow-
release oxycodone/naloxone combinations designed to
reduce OIC, a new and specific questionnaire was de-
veloped. This is termed the Bowel Function Index (BFI)
and is a clinician-administered questionnaire to evaluate
and assess OIC. The BFI has been validated against the
Patient Assessment of Constipation Scale, bowel move-
ments, and laxative use, with excellent correlation being
found [61].
For OIBD, there is no valid assessment tool specifically
designed to measure the burden of these symptoms.
Instruments such as the Gastrointestinal Symptom
Rating Scale are well validated for general GI symptoms
and are available in many languages [62]. However,
sensitivity to opioid-induced adverse events will require
further investigation. The questionnaire will also require
supplementary questions to increase its specificity for
OIBD. Recently the use of several outcome variables
based on objective measures (e.g., bowel movements),
patient-reported assessment with questionnaires, and a
global measure of burden such as life quality were sug-
gested [48]. Future studies are, however, needed to ex-
plore the reliability and validity of these tools.
Objective Assessment of OIBD Has Focused on
Motility, but There Are Only a Few Human Studies
on Opioid Effects on Secretion and Sphincter
Function
Comment: Self-reported number of bowel movements
and time to bowel movement may be used as objective
measures of OIC. The feces can be quantified with
semi-objective questionnaires such as the Bristol Stool
Form scale [60]. When it comes to more physiological
measurements, most studies have focused on motility
disturbances where transit time was measured in differ-
ent ways [63,64].
No methods are able to estimate the total flux of water
in the human intestine. Fecal collection and measure-
ment of water content is possible, but difficult to use in
clinical practice. Secretion of water from the gut mucosa
can be directly assessed from biopsies in an Ussing
chamber [65]. It is also possible to quantify the amount
of feces within the colon based on magnetic resonance
scanning, but no such studies have yet been performed
to address OIBD [66,67].
Sphincter tone has been shown to be increased follow-
ing opioid treatment; however, there is only one study
that has demonstrated a pressure increase of the
human internal sphincter during opioid treatment
[68,69]. Methods such as the Functional Lumen
Imaging Probe and high-resolution manometry may in-
crease our knowledge about anal sphincter function in
the near future [70,71].
Prevalence
Data on Prevalence of OIC Differs Widely Based on
the Definitions Used and Origin of the Studies, but
Not on Gender
Comment: The prevalence of constipation was reported
in 22–81% of patients [14,20]. Prevalence rates relate to
the instrument used—in a study of 520 individuals, the
prevalence was 59% according to the BFI, 67% using
the Knowles–Eccersley–Scott symptom score, and 86%
according to the clinician’s opinion [37]. Prevalence of
OIC is not related to gender (odds ratios ¼ 1:1.25
male:female) [30].
The Type of Pure Opioid Drugs Does Not Influence
the Prevalence of OIC Symptoms
Comment: One placebo-controlled study of opioids
showed a 14% rate of constipation with placebo vs 39–
48% for various forms of oxycodone and oxymorphone
[72]. A review of different opioids showed no difference
in rates of OIC between morphine, hydrocodone, and
hydromorphone [73]. A recent approach to reduce OIC
is through dual action drugs. One of these, tapentadol,
is an opioid with classic l-agonistic properties that also
has simultaneous action as a noradrenaline reuptake in-
hibitor [74]. Hence, for an equianalgesic dose, less l-
agonism is required in opioid-naı¨ve patients [75–77].
However, experienced pain specialists have seen with-
drawal when patients have been switched from long-
term treatment with potent opioids to an “equipotent”
dose of tapentadol without first tapering the opioid.
Dose and Frequency of Opioids Influences
Likelihood of OIC Symptoms
Comment: In one study, daily use of opioids led to re-
ports of constipation in 81% of patients, whereas only
46% of patients using opioids two to three times per
week reported constipation [20]. The study documented
that daily opioid users tended to take more than one
type of opioid.
Transdermal Preparations of Fentanyl and
Buprenorphine May Be Associated with Lower
Incidence of OIC than Oral Opioids
Comment: The rates of constipation reported for trans-
dermal opioids are numerically lower than for oral opioids.
In a nonrandomized, retrospective study, the rates of
constipation were 3.7% for transdermal fentanyl, 6.1%
for oxycodone controlled-release (CR), and 5.1% for mor-
phine CR [78]. Similar findings, reproducing these ex-
tremely low incidences of OIC, were seen with fentanyl
patch (5%) vs morphine (6%) [79]. A systematic review of
14 studies on buprenorphine showed lower rates of
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constipation for buprenorphine than for morphine and
similar rates to those reported for fentanyl. However,
there were no direct comparisons of the two transdermal
opioids [80]. Patch administration of buprenorphine does
indeed cause constipation. A buprenorphine patch (me-
dian dose 10 ug/hour) caused constipation in 24% of
100 osteoarthritis patients compared with only 5% in the
placebo-patch group [81]. The opioid, when released
from the patch, will still reach the intestinal circulation
and enteric nervous system and, therefore, may exert its
inhibitory effect on motility. However, the more uniform
blood opioid concentration provided by the patch, par-
ticularly in regards to reduced peaks in concentration,
may be advantageous. It is also important to remember
that caution must be taken when interpreting the
prementioned data as there are no high-quality compara-
tive trials between oral and transdermal opioids.
Duration of Opioid Therapy Influences the Impact of
OIC Symptoms
Comment: A systematic review of 11 studies, including
2,877 patients with nonmalignant pain, identified that
opioid treatment for more than six weeks significantly
improved QoL and functional outcomes [82]. However,
patients who had been taking opioid analgesia for more
than six months and suffering OIC had a higher impact
on their QoL, as well as impairment of in-work product-
ivity and activities of daily living (in all comparisons), and
greater work time was missed than for patients without
OIBD [83]. Though this statement is based on an indir-
ect comparison, we do know that opioid treatment for
more than six weeks can improve QoL and that there is
a difference in impact on QoL between patients with
OIC and without OIC. As such, there needs to be a
judgment made that balances the benefits of chronic
opioid usage against the risks of intestinal symptoms.
Mechanisms of OIBD
Opioid Receptors Are Spread Throughout the GI
Tract from the Mid-Esophagus to Rectum and Are
Involved in a Variety of Cellular Functions
Comment: d-, j-, and l-opioid receptors have been
identified in the GI tract [84]. These receptors are pre-
dominantly found in the enteric nervous system, but their
relative distribution varies within regions and histological
layers of the gut and, most importantly, between species
[85,86]. In rats, l-receptors are widely distributed in the
myenteric plexus, where they control motility, as well as
in the submucosal plexus, where they mainly regulate ion
and water transport [85–88]. The endogenous opioid lig-
ands (e.g., enkephalins, endorphins, and dynorphins)
have correspondingly been localized in the same regions
[89]. In humans, the distribution of the different opioid re-
ceptors and subclasses is less thoroughly investigated,
but m-receptors in the enteric nervous system are
thought to be of utmost importance [86].
Endogenous ligands play a role in normal regulation of
GI function, but opioid receptors are also activated by
exogenous opioids [86,90,91]. Opioid-induced intracel-
lular signaling is complex, but leads to decreased neur-
onal excitability and less neurotransmitter release,
resulting overall in an inhibitory effect on the cells. The
main effect is thought to be decreased formation of cyc-
lic adenosine monophosphate, a molecule involved in
the activation of several target molecules that regulate
cellular functions [92]. The effect opioids have on GI
motility and secretion is further complicated by opioid
receptor agonists’ ability to influence both excitatory
and inhibitory activity, as well as activating the interstitial
cell of the Cajal–muscle network [84].
Opioid Agonists Administration Results in Slowing
of Normal GI Motility, Segmentation, Increased
Tone, and Uncoordinated Motility Reflected in, for
Example, Increased Transit Times
Comment: Gut motility is mainly controlled by the my-
enteric plexus. This is dependent on neurotransmitters
where acetylcholine activates the motor neurons in the
longitudinal smooth muscles, whereas vasoactive intes-
tinal peptide and nitric oxide control the inhibition of in-
hibitory motor neurons in the circular smooth muscles
[49,93]. As opioid administration inhibits the release of
the neurotransmitters, it directly results in an increase in
tone and a decrease in the normal propulsive activity. l-
opioid receptors are likely of most importance as the ef-
fect of morphine on GI motility is absent in l-receptor
knockout mice [94]. Central effects of opioids on motility
may play a role via sympathetic activation, but are likely
to be of minor importance [95].
The results of the animal experiments were confirmed
in vitro on isolated human gut strips [96]. Furthermore,
in vivo human studies have confirmed that opioid ad-
ministration leads to dysmotility of the esophagus and
gallbladder and increase of tone in the stomach [93,97–
99], as well as a delay in gastric emptying, oral-coecal
transit, and colonic transit time [64,69,100].
Although confirmation is required in other species, a re-
cent study in mice suggests that the effect of opioids
on the gut, may vary between opioids [101]. Hence, opi-
oids such as tapentadol, which have effects on the nor-
adrenergic system, may preserve the analgesic effects
with fewer adverse effects on the gut [102].
Opioids Result in Increased Absorption and
Decreased Secretion of Fluids in the Gut, Leading
to Dry Feces and Less Propulsive Motility
Comment: Opioids inhibit acetylcholine release, which
can lead to a decrease in saliva production, resulting in
the symptom of dry mouth. In the gut, the submucosal
plexus controls local secretory and absorptive activity
Clinical Guidelines for OIC and OIBD
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[59,103]. Acetylcholine, along with serotonin and
vasoactive intestinal peptide, is released from neurons
activating intracellular mechanisms in mucosa cells and,
subsequently, epithelial cell chloride channels. As chlor-
ide moves from the enterocyte cytoplasm into the gut
lumen, water follows via an osmotic gradient
[91,101,104].
Opioids bind to the secretomotor neurons in the sub-
mucosa and suppress neurotransmitter release, result-
ing in a decrease in chloride and water secretion [91]. In
this way, gut secretion and absorption is affected to-
gether with gastric and pancreatico-biliary secretion
[85,105,106].
The slowing of gut motility also allows more time for
water absorption. A decrease in fecal volume has a
negative effect on motility as the intrinsic reflexes that
result in propulsive contractions are dependent on
mechanoreceptor activation [85].
Opioids Increase Sphincter Tone, Which May Cause
Symptoms Such as Sphincter of Oddi Spasms and
Difficult Defecation
Comment: The effect of opioids on the lower esopha-
geal sphincter in humans remains unclear. Most volun-
teer studies have shown an increase in resting pressure
but an abnormal coordination [107,108]. In patients with
reflux, morphine was shown to reduce the number of
transient sphincter relaxations, but in some experiments
there was an increased incidence of gastro-esophageal
reflux [109,110]. However, many of the studies were
flawed by methodological limitations. New devices, such
as the functional lumen imaging probe (EndoFLIP), may
clarify how opioids interfere with esophageal function
[111].
The effect on the pylorus was investigated by Stacher
et al. (1992), who documented increased tone, which
will invariably worsen gastro-esophageal reflux [112].
Morphine administration results in sphincter of Oddi
contractions, leading to a decreased emptying of pan-
creatic juice and bile, and therefore delayed digestion
[113]. It has been observed that patients on opioid ther-
apy may experience acute biliary pain attacks [114,115].
Opioid-induced sphincter of Oddi dysfunction has also
been described in patients addicted to opioids, present-
ing findings such as pancreatobiliary pain and dilation of
the bile duct [68].
The ileal brake has only been investigated in animal
studies, where it was shown that endogenous opioids
contribute to the stomach-to-caecum transit [116].
Opioid-induced dysfunction of the ano-rectal physiology
is particularly relevant as sphincter dysfunction can result
in straining, hemorrhoids, and/or incomplete evacuation,
which are worsened by constipation. The significance of
anal sphincter dysfunction in OIBD has only been
sparsely assessed [69], but preclinical studies indicate
that opioids not only inhibit relaxation of the internal anal
sphincter, but also the detection of stool in the upper
anal canal [117,118]. This is in line with a recent study of
patients treated with opioid analgesics, where one-third
of patients had feeling of anal blockage [30].
Opioid Antagonists Counteract the Effects of
Opioids in the Human Gut on Motility, Fluid
Transport, and Sphincter Function
Comment: Antagonism of l-receptors has been shown
to reverse the effect of opioids on gut motility in numer-
ous animal studies [89,119,120]. In humans, opioid an-
tagonists reversed the effect of opioids on the
esophagus and stomach and increased gut motility in
the intestine [64,110,121–125]. It should be noted that
some studies found no effect of opioid antagonists
(e.g., on motility in the stomach and small intestine), but
this may be explained by methodological limitations
[90,97]. Consistent with the physiological experiments,
pilot clinical studies have shown that naloxone can im-
prove chronic idiopathic gastric stasis, “normal” consti-
pation, and chronic idiopathic pseudoobstruction
[100,126–128].
Preclinical studies have shown that antagonists of d-re-
ceptors reverse the effects of opioids on secretion
[113]. However, there is a lack of human physiological
studies; the effect of antagonists on secretion has not
been addressed, although relief of evacuation problems
due to dry feces is frequently reported [129].
Opioid antagonists were shown to eliminate the effect of
opioids on sphincter function in preclinical studies [114].
In humans, the effect of morphine and pethidine on
sphincter of Oddi contractions was also reduced by na-
loxone [130].
QoL
QoL Can Be Worse due to Side Effects of Opioids
Comment: Patients with moderate-to-severe pain who
receive opioid analgesic treatment for their pain often
experience a secondary burden due to the adverse ef-
fects of opioids (for example, OIC) [59,131].
Many of the adverse events associated with opioid anal-
gesics may subside due to tolerance. However, the
symptoms of OIC often persist for some time, resulting
in a significant impact on patients’ QoL [59]. In patients
taking opioids, constipation may be more distressing for
the patient than the underlying pain. In a large interna-
tional survey of patients treated with opioid therapies for
six or more months, patients suffering from constipation
were more likely to visit their physician, take time off
Mu¨ller-Lissner et al.
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work, and feel that their work productivity and their cap-
ability of performing daily activities was impaired com-
pared with those who did not experience constipation
[83].
Assessment of QoL in Patients with OIC/OIBD Can
Assist Therapeutic Choices
Comment: As reviewed recently, numerous assessment
tools, both generic (such as SF-36/EQ5D, etc.) and
constipation specific (such as PAC-QoL), are used to
assist therapeutic choices and evaluate QoL in consti-
pated patients in general, and in patients with OIC/OIBD
in particular [132]. One special type of general QoL
measure is the utility value, which is usually measured
between 0 and 1, where perfect health is given a score
of 1. A number of studies have shown a reduction in
QoL as a result of constipation. A study of patients who
were treated with opioid analgesics and had a severe
noncurable disease and relatively short life expectancy
used the EuroQoL five-dimension questionnaire (EQ-5D)
to measure QoL. The EQ-5D score in patients without
advanced illness who did not experience constipation
was much higher (0.65) than the score for patients with
constipation (0.31) [27]. In a study on QoL in patients
with chronic functional constipation, a cost-effectiveness
model that measured health outcomes by number of
quality-adjusted life-years demonstrated a small 1%
health benefit for one laxative over another [133].
Nonpharmacological Prevention and Treatment of OIC
Nonpharmacological Treatments of OIC Include
Dietary Recommendations and Lifestyle
Modifications
Comment: In patients with OIC, no study in the current
literature has tested the efficacy of nonpharmacological
treatments. In subjects with chronic idiopathic constipa-
tion, there is no evidence that increasing fluid intake,
unless there is co-existent dehydration, is an effective
treatment.
In nonopioid-induced constipation (i.e., chronic idio-
pathic constipation), increasing soluble dietary fiber,
psyllium, or ispaghula may improve symptoms
[134,135]. Finally, moderate-to-intense physical activity
may improve moderate chronic idiopathic constipation
[134]. With regard to OIC, standard daily fluid and fiber
intakes should be recommended, although this is not
evidence based. However, increases in physical activity
might be difficult to obtain in patients with chronic pain
requiring treatment with opioids.
If narcotic bowel syndrome is suspected to contribute
to the symptoms, tapering or withdrawal of opioids
should be tried and pain should be treated by alterna-
tive measures [136].
Pharmacological Prevention and Treatment of OIC/
OIBD
The Choice of a Laxative to Treat OIC/OIBD
Depends on the Perceived Efficacy and the
Preference of the Patient; Indirect Evidence Favors
Bisacodyl, Sodium Picosulfate, Macrogol
(Polyethelene Glycol), and Sennosides as First
Choice
Comment: Both bisacodyl (and its derivative sodium
picosulfate) and sennosides stimulate secretion and are
very potent prokinetics in the colon. Their prokinetic ac-
tion may potentially also be active in the more oral seg-
ments of the gut [137–139]. Bisacodyl is used as the
rescue laxative in most of the therapeutic trials for OIC,
and the amount taken is considered a sensitive variable
for the efficacy of the drug under investigation [32–
34,43,140–142]. Macrogol and sugars, such as lactu-
lose, act by binding water. Macrogol and lactulose
proved to be significantly superior to placebo, macrogol
being numerically better than lactulose (Table 1) [142].
When the choice of the rescue laxative was decided by
OIC patients, in one study approximately 80–90% of pa-
tients preferred a “stimulant laxative” (bisacodyl or
senna) [22], whereas in another study macrogol and so-
dium picosulfate were the preferred laxatives [147].
Hence, bisacodyl, sodium picosulfate, sennosides, and
macrogol appear to have similar efficacy in OIC [147].
Preventive administration of laxatives to 720 adult
Japanese patients treated with oral opioid analgesics for
the first time was effective in preventing OIC (defined as
a stool-free interval of72 hours). The most frequently
prescribed laxatives were magnesium oxide and senna.
There were no apparent differences in the efficacy be-
tween laxatives [148].
Of importance is that many patients are not informed (or
do not recall that they have been informed) about con-
stipation and laxatives when opioids are prescribed.
Hence, in a recent interview study at the pharmacy with
patients having their first opioid prescription, only 28%
remembered having received information about the risk
of constipation and 13% were prescribed laxatives or
instructed to request them [149].
Sugars and Sugar Alcohols Such as Lactulose,
Lactose, and Sorbitol Should Not Be Used to
Prevent or Treat OIC
Comment: Metabolism of sugars and sugar alcohols by
the intestinal microbiota leads to short chain carbonic
acids and gas. The ensuing abdominal distension may
aggravate distension in OIBD [150,151]. Lactulose and
polyethylene glycol were studied in a controlled trial that
comprised of 308 critically ill patients with multiple
organ failure and mechanical ventilation. Intestinal
Clinical Guidelines for OIC and OIBD
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pseudo-obstruction or Ogilvie’s syndrome occurred in
5.5% of patients in the lactulose group, and in 1.0% of
patients in the macrogol group [152]. Lactulose seems
similarly effective to treat OIC as senna [144], though
numerically inferior to macrogol (Table 1) [143], and it
should therefore not be considered first choice.
Gastro-Oesophageal Reflux Symptoms as Part of
OIBD Should Be Treated like Primary Reflux
Disease
Comment: There are no published therapeutic trials on
gastro-esophageal reflux as part of OIBD, but there is
no reason to assume that conventional reflux treatment
could not ameliorate reflux symptoms in OIBD.
Patients with Nausea Secondary to Opioid
Treatment Should Be Offered Dopamine
Antagonists
Comment: Published evidence shows no or only minor
positive effects of metoclopramide on nausea and vom-
iting when morphine was given parenterally in acute
pain [153,154]. However, when given for chronic pain,
positive results on nausea were reported in an uncon-
trolled study [155]. Data on the neurokinin-1-receptor-
antagonist aprepitant are insufficient to recommend its
use [156].
Treatment of OIC with New Laxatives (Prucalopride,
Lubiprostone) May Be Promising; However, to Date,
There Are Insufficient Data to Warrant Such
Treatments in OIC Patients
Comment: In recent years, a few new drugs have been
proposed for the medical treatment of patients with
chronic constipation [157]. Among these, prucalopride
(a potent and highly selective agonist of 5-HT4 serotonin
receptors) [158] and lubiprostone (a chloride [Cl-] chan-
nel activator derived from prostaglandin E1) [159] are
currently sold in Europe and the United States, respect-
ively. Both these drugs have also been tested in pa-
tients complaining of OIC (Table 1). Concerning
prucalopride, there is only one published study available
showing that both the 2 mg and 4 mg once-daily doses
significantly increase spontaneous bowel movements in
these patients, but only during the first two weeks of
treatment [29]. Concerning lubiprostone, the available
data (two published studies [142,145] and four ab-
stracts [38,40,41,44]) seem to suggest that the drug
may be useful in the treatment of OIC, even though it is
possible that this effect is limited to some subtypes of
patients. Compared with placebo, lubiprostone was
able to improve symptoms related to OIC [142]. Another
Figure 2 Treatment guidance algorithm for patients initiating opioid treatment and patients presenting with OIC.
Patients with previous constipation not responding well to laxatives and given an opioid therapy on top are probably
best treated with an agonist-antagonist plus a laxative. *First choice laxatives—bisacodyl, sodium picosulfate, senna,
macrogol. OIC ¼ opioid-induced constipation.
Clinical Guidelines for OIC and OIBD
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study showed no advantage over the less expensive
senna [145].
Peripherally Acting l-Opioid Receptor Antagonists
Peripherally Acting l-Opioid Receptor Antagonists
Effectively Reduce OIC
Comment: Attempts have been made to develop opioid
antagonists that block peripheral opioid receptors and
reduce OIC. They do not have access to opioid recep-
tors within the central nervous system and therefore
spare central analgesic opioid function. Sixteen RCTs
on the following four peripherally acting l-opioid recep-
tor antagonists (PAMORAs) have been identified: nalox-
one (either alone or in fixed-ratio combination with
oxycodone), methylnaltrexone, naloxegol, and alvimo-
pan. On the whole, they provide evidence for efficacy of
PAMORAs for OIC, and partly also for OIBD [160].
In Patients with Chronic Cancer or Noncancer Pain,
Prolonged-Release Naloxone/Oxycodone
Combination Effectively Reduces OIC While
Maintaining Equal Analgesia to Prolonged-Release
Oxycodone Alone
Comment: Following oral administration, naloxone has
nearly no systemic bioavailability due to extensive first-
pass hepatic metabolism [161]. Therefore it acts almost
exclusively on opioid receptors in the GI tract and
spares central analgesia. Prolonged-release (PR) nalox-
one/oxycodone combination was tested in four RCTs in
974 patients with chronic pain [18,23,35,160].
Oxycodone dose per 24 hours ranged between 40 mg
and 120 mg, and trial duration from four to 12 weeks.
Oxycodone/naloxone (2:1 fixed ratio)-treated patients
exhibited improved BFI, the primary outcome in all stud-
ies, compared with those treated by oxycodone/placebo
(mean difference ranged from 11.1 to 17.5 points
across studies) (Table 2). No serious adverse events
were reported. Notably, one RCT tested the effect of
2 mg or 4 mg of naloxone (not prolonged release) alone,
or placebo, in nine patients taking stable doses of opi-
oids who had OIC [13]. Oral naloxone-treated patients
had some improvement in bowel frequency, but reversal
of analgesia was experienced by three of the nine
patients.
Oral Naloxegol Is Effective and Safe in Reducing
OIC in Patients with Chronic Pain
Comment: Naloxegol, a PEGylated derivative of nalox-
one, is taken orally and is not transported across the
blood-brain barrier. Results of three trials in more than
1,500 patients show that, at a daily dose of 25 mg, the
number of days per week with spontaneous and normal
bowel movements increased significantly compared with
placebo (Table 3). Pain intensities and opioid
requirements did not change, and no withdrawal symp-
toms or serious cardiovascular events were observed
[42,43]. The advantage of the drug is that it can be
used orally in the community regardless of the opioid
taken by the patient.
Methylnaltrexone Injections Can Effectively Relieve
OIC in Patients with Postoperative Cancer and
Noncancer Chronic Pain
Comment: Due to its chemical structure, methylnaltrex-
one does not cross the blood-brain barrier and acts
only peripherally. The five identified RCTs in this cat-
egory (>800 patients) varied considerably in terms of
number of randomized patients (22 to 460), treatment
duration (single dose to four weeks), diagnosis (cancer
pain, chronic noncancer pain, methadone maintenance),
and dose (0.15 mg/kg; 0.30 mg/kg or 12 mg adminis-
tered daily or every other day, intravenously, or by sub-
cutaneous injection) [12,22,25,34,36]. The outcome in
most studies was either time to first bowel movement
after the injection or, more commonly, the percentage
of patients achieving bowel movement within two to
four hours of treatment. All studies showed significantly
better outcome with methylnaltrexone compared with
placebo (Table 4). Secondary outcomes such as
decreased laxative use also improved. The treatment
was generally well tolerated, although cases of GI per-
foration in association with methylnaltrexone use have
been reported [163]. Recent findings suggest that meth-
ylnaltrexone can lead to increased morphine demands
for postoperative pain control [164].
Alvimopan Is Approved in the United States for Use
in Hospitalized Patients for Preventing or
Decreasing the Course of Postoperative Ileus After
Bowel Resection; Long-Term Safety Studies
Indicated that It May Possibly Increase the Risk of
Cardiovascular Events; There Is Some Evidence
that Alvimopan Reduces OIC in Subjects with
Chronic Opioid Intake
The selective peripheral action of alvimopan is related to
its large molecular size and zwitter-ionic form. Four
RCTs studied alvimopan in OIC in more than 1,500 pa-
tients for preventing or decreasing the course of
postoperative ileus after bowel resection (Table 5). Two
of them showed a significant improvement in the num-
ber of patients demonstrating bowel movements, the
number of bowel movements, and/or reduced duration
of time to first bowel movement [15,19]. However, the
primary end point of three spontaneous bowel move-
ments per week in two other studies was not [32], or
was only partly, met [33]. Notably, opioid-naı¨ve patients
with “acute OIC” need much higher doses of alvimopan
(12 mg) to reduce the length of postoperative ileus after
bowel surgery than patients with chronic opioid treat-
ment (1–2 mg) [165].
Mu¨ller-Lissner et al.
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Three other PAMORAs are being developed for OIC
[47,166]: bevenopran (Cubist Pharmaceuticals), TD-
1211 (Theravance, South San Francisco, CA, USA), and
naldemedine (S-297995, Shionogi, Osaka, Japan). An
oral form of methylnaltrexone is also under development
for treating OIC in patients on opioid therapy for chronic
noncancer pain. Clinical RCT data are not available.
Both Laxatives and Opioid Antagonists for OIC
Have Benefits on QoL
Comment: In the trials evaluating a fixed combination of
prolonged-release oxycodone/naloxone, bowel function
and QoL were investigated using the BFI and other tools.
In the three phase III trials, performed with the majority of
patients with moderate-to-severe nonmalignant pain, sig-
nificant improvements in constipation were observed in
patients taking PR oxycodone/naloxone compared with
those taking PR oxycodone. The improvement in consti-
pation was generally seen within one week of treatment
and lasted the duration of the trials [18,23]. In an
assessment of PR oxycodone/naloxone, using the QoL
tool SF-36, significant improvements were observed in
the subscales of social functioning, vitality, and general
health at week 12 of treatment [167].
A large noninterventional study of clinical practice
observed improvements in QoL for PR oxycodone/
naloxone-treated patients. Patients with severe chronic
pain of various etiologies treated with PR oxycodone/
naloxone demonstrated significant reductions in consti-
pation in both opioid-naı¨ve and opioid-tolerant patients
[168]. The Short-Form Brief Pain Inventory demon-
strated an improvement of 43% (in 2023 patients) after
four weeks of treatment [168].
In an RCT, both senna and lubiprostone improved QoL
and constipation-related symptoms in OIC in postopera-
tive orthopedic patients treated with opioids, with no
significant between-group differences [158].
Noncancer patients taking prucalopride reported a
greater improvement in their constipation severity and
the efficacy of treatment than patients taking placebo,
as measured by the patient-reported PAC-SYM and
PAC-QoL questionnaires (patient assessment of consti-
pation symptoms and patient assessment of constipa-
tion symptoms and quality of life, respectively) [140].
However, the effect was only significant during the first
two weeks of treatment.
Patients with OIC treated with 25 mg naloxegol once
daily, a peripherally acting l-opioid receptor antagonist,
reported improved median total patient-reported scores
on the PAC-QoL questionnaire compared with patients
taking placebo. During the double-blind treatment
period, the 25 mg naloxegol group reported a statistic-
ally significant improvement in SF-36 scale scores for
mental health, social functioning, physical functioning,
and vitality compared with patients receiving placebo.
There was no significant difference between placebo
and the 5 mg and 50 mg naloxegol dose groups [42].
Summary and Conclusions
OIBD is an increasing problem due to the wider use of
opioids, including the treatment of nonmalignant pain.
Current knowledge is certainly insufficient regarding
many aspects of OIC, and more so of OIBD as reflected
by our votes regarding the level of evidence (Appendix).
Though this holds particularly true for the management
of the opioid side effects on the upper GI tract, recom-
mendations can be derived from what we know at pre-
sent (Figure 2). As only about half of the patients taking
opioid experience OIC, a general comedication with a
laxative or an opiate antagonist would be an overtreat-
ment. Rather, awareness of the problem is mandatory
for the treating physician. In addition, prophylaxis could
be adjusted to the perceived risks of OiC in a particular
patient; for example, it could be prescribed to those
who have had constipation as a problem before starting
opioids. However, this issue deserves further study in
the future.
The conventional laxatives, bisacodyl, sodium picosul-
fate, macrogol, and senna, seem to be the first choice
to treat OIC. The new laxatives, linaclotide, lubiprostone,
and prucalopride, may also be effective in selected pa-
tients but do not seem to be superior to PAMORAs
based on the presently available indirect comparisons.
PAMORAs clearly have a proven effect on OIC. Whether
PAMORAs have advantages over laxatives through the
addressing of OIBD, and not only OIC, needs to be
shown in randomized double-blind comparative trials.
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APPENDIX
Studies on OIBD were identified with the terms: Nausea
or heartburn or regurgitation or fullness or dyspepsia or
vomiting or appetite or distension or bloating or abdomi-
nal pain or abdominal discomfort or constipation or gas-
trointestinal transit or slow transit or delayed transit or
colon transit or defecation or abnormal defecation or dif-
ficult defecation or dysmotility or hypomotility or motility
disorder or motility dysfunction or straining or stool or
stool evacuation or incomplete evacuation or hard stools
or infrequent stools or toilet or bowel function or bowel
movement.
These were combined using the set operator AND with
studies identified with the terms: Opiate alkaloids or opi-
ate analgesics or opiate or opioid or narcotics or mor-
phine or oxycodone or fentanyl or tramadol or codeine
or hydromorphone or buprenorphine or methadone or
hydrocodone or tapentadol or levorphanol or propoxy-
phene or tilidine.
Studies were further categorized as relating to preva-
lence, mechanism of OIBD, non-pharmacologic treat-
ment, pharmacologic treatment and opiate antagonists
by combining the results above and five further sets of
search terms.
To identify studies relating to prevalence, the initial
results were combined, using the set operator AND,
with the terms: Epidemiology or prevalence or frequency
or occurrence or population or cost or burden or
economic.
To identify studies relating to mechanisms of OIBD, the
initial results were combined, using the set operator
AND, with the terms: Motility or reflux or esophageal
motility or gastric emptying or colon motility or intestinal
motility or small intestinal motility or secretion or salivary
secretion or intestinal secretion or inhibition or sphincter.
To identify studies relating to non-pharmacologic treat-
ments, the initial results were combined, using the set
operator AND, with the terms: Dietary fiber or ispaghula
or plantago or linseed or flaxseed or flax seed or
wholegrain or dietary fiber or bulking agents or physical
activity or physiotherapy or exercise or sport or drink or
fluid intake or acupuncture or massage or osteopathy.
To identify studies relating to pharmacologic treatments,
the initial results were combined, using the set operator
AND, with the terms: Laxative or macrogol or polyethy-
leneglycol or PEG or lactulose or sobitol or bisacodyl or
picosulfate or senna or sennoside or danthron or sero-
tonin receptor agonist or 5-HT 4 receptors agonist or
guanylate cyclase or chloride channel or prucalopride or
lubiprostone or linaclotide or erythromycin or
neostigmine.
In total, the search yielded 10,832 unique citations. For
inclusion, all studies were required to be performed in
an adult population who were receiving opioid or opiate
drugs and who had a confirmed diagnosis of OIBD
based on clinical symptoms, physician’s opinion, or
specific diagnostic criteria specified by study investiga-
tors. Citations identified within the treatment categories
were also required to be randomized controlled trials,
comparing pharmacologic or non-pharmacologic thera-
pies with a control measure. There was no minimum
duration of therapy, but quantitative assessment of
response to therapy was required. Where trials deemed
it necessary, results should be supplemented by nega-
tive investigations. Only publications published in the
English language were included in the analysis.
Using the above inclusion and exclusion criteria, the
identified citations were screened independently by two
investigators for relevance; by title and then abstract to
reduce the citation list to 124 and then 52 citations,
respectively. Full publications of the 52 citations were
assessed and following discussion to resolve any dis-
agreement, a final list of 33 citations was generated
[12–44].
Voting results table: Votes for each statement with an
accompanying level of agreement, the strength of the
evidence and the strength of the recommendation
(when applicable).
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Statement
Level of agreement
Agree/neutral/
disagree
Level of evidence
Strong/ moderate/
weak
Strength of
recommendation
Strong/ weak
1.1 The definition of OIC/OIBD is based on a clinical evaluation
relating to a change in bowel habits during opioid therapy
10/0/0 0/6/4
1.2 The symptoms of OIC are related to the colon, whereas
OIBD manifests with symptoms throughout the GI tract
10/0/0 0/0/10
1.3 Subjective reports of OIC are based on validated question-
naires, whereas there is no consensus about assessment of
OIBD
10/0/0 9/1/0
1.4 Objective assessment of OIBD has focused on motility, but
there are only a few human studies on opioid effects on
secretion and sphincter function
10/0/0 4/6/0
2.1 Data on prevalence of OIC differs widely based on the defi-
nitions used and origin of the studies, but not on gender
10/0/0 4/6/0
2.2 The type of pure opioid drugs does not influence the preva-
lence of OIC symptoms
10/0/0 0/10/0
2.3 Dose and frequency of opioids influences likelihood of OIC
symptoms
10/0/0 0/7/3
2.4 Transdermal preparations of fentanyl is associated with
lower incidence of OIC than oral opioids
6/1/3 1/3/6
2.5 Duration of opioid therapy influences the impact of OIC
symptoms
10/0/0 0/10/0
3.1 Opioid receptors are spread throughout the GI tract from
the mid-oesophagus to rectum and are involved in a variety
of cellular functions
10/0/0 10/0/0
3.2 Opioid agonists administration results in slowing of normal
GI motility, segmentation, increased tone and uncoordinated
motility reflected in e.g., increased transit times agreement
10/0/0 4/6/0
3.3 Opioids result in increased absorption and decreased
secretion of fluids in the gut, leading to dry feces and less
propulsive motility
10/0/0 0/5/5
3.4 Opioids increase sphincter tone, which may cause symp-
toms such as sphincter of Oddi spasms and difficult
defecation
10/0/0 0/10/0
3.5 Opioid antagonists counteract the effects of opioids in the
human gut on motility, fluid transport, and sphincter function
10/0/0 0/10/0
4.1 QoL can be worse due to side effects of opioids 10/0/0 2/8/0
4.2 Assessment of QoL in patients with OIC/OIBD can assist
therapeutic choices
10/0/0 0/10/0
5.1 Non-pharmacological treatments of OIC include dietary
recommendations and life-style modifications
10/0/0 0/0/10 0/10
6.1 The choice of a laxative to treat OIC/OIBD depends on the
perceived efficacy and the preference of the patient. Indirect
evidence favours bisacodyl, sodium picosulfate, macrogol,
and sennosides as first choice
10/0/0 0/4/6 5/5
6.2 Sugars and sugar alcohols such as lactulose, lactose, and
sorbitol should not be used to prevent or treat OIC
10/0/0 0/9/1 3/7
6.3 Gastro-esophageal reflux symptoms as part of OIBD
should be treated like primary reflux disease
10/0/0 0/0/10 0/10
6.4 Patients with nausea secondary to opioid treatment should
be offered dopamine antagonists
9/1/0 0/0/10 0/10
10/0/0 0/10/0 1/9
(continued)
Mu¨ller-Lissner et al.
26
 by guest on D
ecem
ber 31, 2016
http://painm
edicine.oxfordjournals.org/
D
ow
nloaded from
 
Statement
Level of agreement
Agree/neutral/
disagree
Level of evidence
Strong/ moderate/
weak
Strength of
recommendation
Strong/ weak
6.5 Treatment of OIC with new laxatives (prucalopride, lubipro-
stone) may be promising; however, to date, there are insuffi-
cient data to warrant such treatments in OIC patients
7.1 Peripherally acting ?-opioid receptor antagonists
(PAMORAs) effectively reduce OIC
10/0/0 10/0/0 10/0
7.2 In patients with chronic cancer or non-cancer pain, pro-
longed release naloxone/oxycodone combination effectively
reduces OIC while maintaining equal analgesia to prolonged
release oxycodone alone
10/0/0 10/0/0 10/0
7.3 Naloxegol is effective and safe in reducing OIC in patients
with chronic pain
10/0/0 10/0/0 3/6
7.4 Methylnaltrexone injections can effectively relieve OIC in
patients with post-operative, cancer and non-cancer chronic
pain. However, concerns regarding reversal of analgesia and
intestinal perforation in relation to its post-operative use have
been raised
10/0/0 10/0/0 10/0
7.5 Alvimopan is approved for in-hospital use in the USA for
preventing or shortening the course of postoperative ileus
after bowel resection. Long-term safety studies indicated that
it may possibly increase the risk for cardiovascular events.
There is some evidence that alvimopan reduces OIC in sub-
jects with chronic opioid intake
10/0/0 10/0/0
7.6 Both laxatives and opioid antagonists for OIC have benefits
on QoL
10/0/0 3/7/0 10/0
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